发布时间：2026-02-11 14:12 Restylane Refyne and Restylane Defyne are the first Optimal Balance Technology (OBT) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2
This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs3,4
These two new launches underscore Galderma’s accelerating growth across the Japan & Asia Pacific (JPAC) region



ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBTbased hyaluronic acid injectables ever authorized in Japan.1,2The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market.1,2

Restylane Defyne and Refyne
=*=*=*=*=*=
当前为第1/11页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页